Masimo Corp.’s Neutral Rating Reaffirmed at Zacks (MASI)
Masimo Corp. (NASDAQ:MASI)‘s stock had its “neutral” rating reaffirmed by Zacks in a research note issued to investors on Friday. They currently have a $25.00 target price on the stock. Zacks‘s price objective would suggest a potential upside of 4.73% from the stock’s previous close.
Zacks’ analyst wrote, “Masimo Corporation’s EPS beat the Zacks Consensus Estimate in the 2014-first quarter by $0.10 by posting a handsome 39.3% rise to $0.39. Revenues grew 2.8% to $139.8 million but missed the Zacks Consensus Estimate of $144.0 million. For 2014, MASI expects higher revenues of $$588 to $598 million and higher EPS between $1.24 and $1.33 versus 2013. The company’s SET offering may help it become a dominant global player in the pulse oximetry market. However, soft economic recovery raises concern and strong competition is a headwind. We maintain our Neutral recommendation on Masimo and set a target price of $25.00.”
Shares of Masimo Corp. (NASDAQ:MASI) traded down 2.01% during mid-day trading on Friday, hitting $23.39. The stock had a trading volume of 330,009 shares. Masimo Corp. has a one year low of $21.08 and a one year high of $32.20. The stock’s 50-day moving average is $24.2 and its 200-day moving average is $27.30. The company has a market cap of $1.327 billion and a price-to-earnings ratio of 21.11.
Masimo Corp. (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.01. The company had revenue of $139.80 million for the quarter, compared to the consensus estimate of $144.01 million. During the same quarter in the previous year, the company posted $0.28 earnings per share. Analysts expect that Masimo Corp. will post $1.29 EPS for the current fiscal year.
Separately, analysts at Citigroup Inc. reiterated a “hold” rating on shares of Masimo Corp. in a research note on Friday, May 2nd. They now have a $29.00 price target on the stock. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Masimo Corp. has a consensus rating of “Hold” and an average price target of $27.33.
Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.